Literature DB >> 19324870

Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C.

John Brognard1, Matthew Niederst, Gloria Reyes, Noel Warfel, Alexandra C Newton.   

Abstract

PHLPP2 (PH domain leucine-rich repeat protein phosphatase 2) terminates Akt and protein kinase C (PKC) activity by specifically dephosphorylating these kinases at a key regulatory site, the hydrophobic motif (Ser-473 in Akt1). Here we identify a polymorphism that results in an amino acid change from a Leu to Ser at codon 1016 in the phosphatase domain of PHLPP2, which reduces phosphatase activity toward Akt both in vitro and in cells, in turn resulting in reduced apoptosis. Depletion of endogenous PHLPP2 variants in breast cancer cells revealed the Ser-1016 variant is less functional toward both Akt and PKC. In pair-matched high grade breast cancer samples we observed retention of only the Ser allele from heterozygous patients (identical results were observed in a pair-matched normal and tumor cell line). Thus, we have identified a functional polymorphism that impairs the activity of PHLPP2 and correlates with elevated Akt phosphorylation and increased PKC levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19324870      PMCID: PMC2685702          DOI: 10.1074/jbc.M901468200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

2.  Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors.

Authors:  M Andjelković; T Jakubowicz; P Cron; X F Ming; J W Han; B A Hemmings
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.

Authors:  T Maehama; J E Dixon
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

4.  Loss of heterozygosity on chromosome arm 16q in breast cancer metastases.

Authors:  K Driouch; F Dorion-Bonnet; M Briffod; M H Champéme; M Longy; R Lidereau
Journal:  Genes Chromosomes Cancer       Date:  1997-07       Impact factor: 5.006

5.  Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines.

Authors:  K Nakatani; D A Thompson; A Barthel; H Sakaue; W Liu; R J Weigel; R A Roth
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

6.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

7.  Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.

Authors:  A Perren; L P Weng; A H Boag; U Ziebold; K Thakore; P L Dahia; P Komminoth; J A Lees; L M Mulligan; G L Mutter; C Eng
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

8.  Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo.

Authors:  Jesika Faridi; Lihong Wang; Gerda Endemann; Richard A Roth
Journal:  Clin Cancer Res       Date:  2003-08-01       Impact factor: 12.531

9.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors.

Authors:  P M Siegel; D L Dankort; W R Hardy; W J Muller
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

10.  Autocrine signalling through erbB receptors promotes constitutive activation of protein kinase B/Akt in breast cancer cell lines.

Authors:  K M Nicholson; C H Streuli; N G Anderson
Journal:  Breast Cancer Res Treat       Date:  2003-09       Impact factor: 4.872

View more
  21 in total

1.  Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling.

Authors:  Noel A Warfel; Alexandra C Newton
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

2.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

3.  Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

Authors:  Libero Santarpia; Yuan Qi; Katherine Stemke-Hale; Bailiang Wang; Elliana J Young; Daniel J Booser; Frankie A Holmes; Joyce O'Shaughnessy; Beth Hellerstedt; John Pippen; Tatiana Vidaurre; Henry Gomez; Vicente Valero; Gabriel N Hortobagyi; W Fraser Symmans; Giulia Bottai; Angelo Di Leo; Ana M Gonzalez-Angulo; Lajos Pusztai
Journal:  Breast Cancer Res Treat       Date:  2012-04-27       Impact factor: 4.872

Review 4.  Turning off AKT: PHLPP as a drug target.

Authors:  Alexandra C Newton; Lloyd C Trotman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

5.  miR-3117 regulates hepatocellular carcinoma cell proliferation by targeting PHLPPL.

Authors:  Xia Cui; Qingyan Li; Yukai He
Journal:  Mol Cell Biochem       Date:  2016-11-07       Impact factor: 3.396

6.  PHLPP2 Downregulation Contributes to Lung Carcinogenesis Following B[a]P/B[a]PDE Exposure.

Authors:  Haishan Huang; Xiaofu Pan; Honglei Jin; Yang Li; Lin Zhang; Caili Yang; Pei Liu; Ya Liu; Lili Chen; Jingxia Li; Junlan Zhu; Xingruo Zeng; Kai Fu; Guorong Chen; Jimin Gao; Chuanshu Huang
Journal:  Clin Cancer Res       Date:  2015-05-14       Impact factor: 12.531

Review 7.  Protein kinase signaling networks in cancer.

Authors:  John Brognard; Tony Hunter
Journal:  Curr Opin Genet Dev       Date:  2010-11-29       Impact factor: 5.578

8.  Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.

Authors:  Muhan Chen; Dawid G Nowak; Lloyd C Trotman
Journal:  Clin Cancer Res       Date:  2014-06-15       Impact factor: 12.531

9.  Physiological regulation of Akt activity and stability.

Authors:  Yong Liao; Mien-Chie Hung
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

10.  An insight into the molecular genetics of a uveal melanoma patient cohort.

Authors:  Susan Kennedy; Michael Rice; Sinead Toomey; Noel Horgan; Bryan T Hennessey; Annemarie Larkin
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-14       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.